1. Dancer SJ, Kirkpatrick P, Corcoran DS, Christison F, Farmer D, Robertson C. Approaching zero: temporal effects of a restrictive antibiotic policy on hospital-acquired Clostridium difficile, extended-spectrum β-lactamase-producing coliforms and meticillin-resistant Staphylococcus aureus. Int J Antimicrob Agents. 2013;41:137–42.
2. Livermore DM, Hope R, Reynolds R, Blackburn R, Johnson AP, Woodford N. Declining cephalosporin and fluoroquinolone non-susceptibility among bloodstream Enterobacteriaceae from the UK: links to prescribing change?. Chemother: J. Antimicrob; 2013.
3. Aldeyab MA, Harbarth S, Vernaz N, Kearney MP, Scott MG, Darwish Elhajji FW et al. The impact of antibiotic use on the incidence and resistance pattern of extended-spectrum beta-lactamase-producing bacteria in primary and secondary healthcare settings. Br. J. Clin. Pharmacol. 2012;74:171–9.
4. Petrikkos G, Markogiannakis A, Papaparaskevas J, Papapareskevas J, Daikos GL, Stefanakos G, et al. Differences in the changes in resistance patterns to third- and fourth-generation cephalosporins and piperacillin/tazobactam among Klebsiella pneumoniae and Escherichia coli clinical isolates following a restriction policy in a Greek tertiary care hospita. Agents: Int. J. Antimicrob; 2007.
5. LeBlanc L, Pépin J, Toulouse K, Ouellette M-F, Coulombe M-A, Corriveau M-P, et al. Fluoroquinolones and risk for methicillin-resistant Staphylococcus aureus. Canada. Emerg. Infect. Dis. 2006;12:1398–405.